Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

So this secondary is essentially timed to the release of B 2b bottom line data release which is very standard practice for small biotechs which is to raise funds when you can. This should give Leo more control over the stock price controlling when and how much dilution occurs. Rather than giving discounts and not controlling when the shares enter the market..aka Aspire financing.

Should be less dilution...more control..sounds good